Vanguard Group Inc. Has $18.55 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Vanguard Group Inc. trimmed its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 2.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,660,520 shares of the biotechnology company's stock after selling 45,655 shares during the quarter. Vanguard Group Inc. owned about 7.88% of Enanta Pharmaceuticals worth $18,548,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ENTA. Braidwell LP raised its position in Enanta Pharmaceuticals by 218.7% in the first quarter. Braidwell LP now owns 1,038,310 shares of the biotechnology company's stock worth $41,989,000 after acquiring an additional 712,472 shares in the last quarter. Krensavage Asset Management LLC acquired a new stake in Enanta Pharmaceuticals during the first quarter valued at approximately $24,397,000. Assenagon Asset Management S.A. boosted its holdings in Enanta Pharmaceuticals by 613.6% during the third quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company's stock worth $7,055,000 after buying an additional 543,111 shares in the last quarter. Acadian Asset Management LLC grew its position in Enanta Pharmaceuticals by 445.6% in the third quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company's stock worth $6,125,000 after buying an additional 448,201 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Enanta Pharmaceuticals by 29.9% in the second quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company's stock valued at $80,332,000 after buying an additional 390,842 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ENTA shares. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Thursday, February 8th. StockNews.com cut shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, April 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of "Hold" and an average price target of $19.33.

Enanta Pharmaceuticals Trading Down 1.8 %

ENTA stock traded down $0.30 during midday trading on Monday, reaching $16.15. The company had a trading volume of 161,286 shares, compared to its average volume of 267,979. The company has a 50 day moving average of $14.61 and a two-hundred day moving average of $11.63. The company has a market capitalization of $341.73 million, a P/E ratio of -2.46 and a beta of 0.47. Enanta Pharmaceuticals, Inc. has a 1 year low of $8.08 and a 1 year high of $38.79.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million for the quarter, compared to analysts' expectations of $22.74 million. On average, sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.9 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.